Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
DNA: New Method Analyses Changes with ‘Unprecedented Accuracy’
Scientists have developed a new sequencing method to study changes in the DNA of any […]
FDA Grants Accelerated Approval for GSK’s JEMPERLI (dostarlimab-gxly) for Women with Recurrent or Advanced dMMR Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has […]
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
Gain Therapeutics, Inc. today announced a multi-target collaboration agreement with Zentalis Pharmaceuticals to discover new product candidates […]
Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development
Medable Inc. today announced $78 million in new funding to fuel advances in the delivery […]
Oregon Oncology Specialists Integrate AI-screening Solution VIPER™ Into Network
Deep Lens and Oregon Oncology Specialists today announced a strategic collaboration that will integrate Deep […]
LARVOL Launches Cancer-Focused Social Listening Platform
LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today […]
Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers
Early results show that a new combination drug therapy is safe and effective against advanced […]
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials
Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for […]
Hawaii Cancer Care Deploys AI-Screening Tool VIPER ™
Hawaii Cancer Care and Deep Lens today announced a partnership that will expand the clinical trial offering for […]
FDA Approves Abecma for Multiple Myeloma
The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more